

## molnupiravir – An oral treatment for COVID-19 filed for EUA

- On October 11, 2021, <u>Merck announced</u> the submission of an application for emergency use authorization (EUA) to the FDA for molnupiravir, an oral treatment for COVID-19.
- Molnupiravir is a ribonucleoside analog that inhibits the replication of SARS-CoV-2, the virus responsible for COVID-19.
- Molnupiravir is intended for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization.
- The EUA submission is based on a planned interim analysis from the phase 3, randomized, double-blind, placebo-controlled MOVe-OUT clinical trial, which evaluated 775 non-hospitalized, unvaccinated adult patients with mild-to-moderate COVID-19 who were at risk for progressing to severe COVID-19 and/or hospitalization.
  - At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% (28/385) of patients who received molnupiravir were either hospitalized or died through day 29 following randomization vs. 14.1% (53/377) of placebotreated patients (p = 0.0012).
  - Through day 29, no deaths were reported in patients who received molnupiravir vs. 8 deaths in patients who received placebo.
  - The incidence of any adverse event was comparable in the molnupiravir and placebo groups (35% and 40%, respectively).
- A second clinical trial is underway: The MOVe-AHEAD trial will evaluate 1,332 individuals for
  preventing the spread of COVID-19 within households (e.g., post-exposure prophylaxis). The test
  dose will be molnupiravir 800 mg every 12 hours for 5 days. Data is expected in the first half of
  2022.
- The U.S. government has paid \$1.2 billion for 1.7 million courses (an oral dose twice daily for 5 days) of treatment if authorized or approved by the FDA.
  - Merck expects to produce 10 million courses of treatment by the end of 2021, and more in 2022.
- Before molnupiravir can be used commercially, the FDA must authorize its use.
  - Since molnupiravir is an oral treatment for COVID-19, it would not be in scope for review by CDC's Advisory Committee on Immunization Practices (ACIP).
  - No FDA Advisory Committee has been scheduled. If a meeting is scheduled, OptumRx will
    monitor it for relevant information.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.